We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

0001193125-10-055444 Sample Contracts

PARTICIPATION AGREEMENT
Participation Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • New York

This Participation Agreement (this “Agreement”) is entered into as of the 22nd day of December, 2006 (the “Effective Date”) by and between BG Medicine, Inc., a corporation having offices at 610 N. Lincoln Street, Waltham, Massachusetts 02451 (“BGM”) and Philips Medical Systems Nederland B.V. a company having offices at Veenpluis 4-6, 5684 PC Best, the Netherlands (“Philips” and “Participant”); each of Participant and BGM are sometimes referred to individually as a “Party” and collectively as the “Parties”).

SUPPLY AGREEMENT
Supply Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • Delaware

Payment to Corgenix for CE-Marking Services is estimated to be $[***] based on details provided in the Proposal dated December 15, 2008.

Research Collaboration
Research Collaboration Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories

This Agreement is entered into effective on this 20th day of January, 2010 (the “Effective Date”) by and between MERCK SHARP & DOHME CORP (formerly Merck & Co., Inc.), having offices at One Merck Drive, Whitehouse Station, NJ 08889 (hereinafter referred to as, “Merck”), and BG MEDICINE, INC., a private diagnostic development services company having offices at 610 Lincoln Street, Waltham, MA 02451 (“BGM”). Hereinafter, Merck and BGM are individually referred to as a “Party,” collectively as the “Parties”.

Participation Agreement
Participation Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • New York

This Participation Agreement (this “Agreement”) is entered into as of the 31st day of March, 2008 (the “Effective Date”) by and between BG Medicine, Inc., a corporation having offices at 610 N. Lincoln Street, Waltham, Massachusetts 02451 (“BGM”) and Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-Chome, Chuo-ku, Osaka 540- 8645, Japan (“Participant”; each of Participant and BGM are sometimes referred to individually as a “Party” and collectively as the “Parties”).

PARTICIPATION AGREEMENT
Participation Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • New York

This Participation Agreement (this “Agreement”) is entered into as of the 28th day of July, 2006 (the “Effective Date”) by and between BG Medicine, Inc., a corporation having offices at 610 N. Lincoln Street, Waltham, Massachusetts 02451 (“BGM”) and Merck & Co., Inc., having offices at One Merck Drive, Whitehouse Station, NJ 08889 (“Participant”; each of Participant and BGM are sometimes referred to individually as a “Party” and collectively as the “Parties”).

CONFIDENTIAL FIRST AMENDMENT TO GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT
Galectin-3 License and Distribution Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories

THIS FIRST AMENDMENT TO GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT (this “First Amendment”) is entered into as of February 3, 2010 (the “First Amendment Date”) by and between Abbott Laboratories, a corporation of the state of Illinois, having its principal place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500 (“Abbott”) and BG Medicine, Inc., a corporation of the state of Delaware, having its principal place of business at 610 Lincoln Street North, Waltham, Massachusetts 02451 (“BGM”).